Table 2.
EBV and CMV seroprevalence and antibodies titers in MS patients and controls
| Healthy controls (HC) | Multiple sclerosis patients (MS) | Relapsing–remitting MS patients (RR-MS) | Progressive MS patients (P-MS) | |
|---|---|---|---|---|
| EBV seroprevalence (%) | 100 | 100 | 100 | 100 |
| EBNA-1 IgG (U/ml) | 782.55 (627.82–910.95) | 1009.23* (782.79–1383.37) | 1139.00* (782.70–1452.15) | 937.29** (828.82–1191.21) |
| VCA Ab (U/ml) | 375.54 (144.77–625.19) | 969.07** (511.62–1340.41) | 1146.45** (560.95–1407.95) | 885.15 (277.02–1050.24) |
| CMV seroprevalence (%) | 64.3 | 70.2 | 69.7 | 71.2 |
| CMV IgG (U/ml) | 58.40 (38.15–84.47) | 83.40 (46.33–119.56) | 80.87 (46.78–124.58) | 86.68 (55.04–112.95) |
Data are expressed as medians and (interquartile range)
EBV Epstein-Barr Virus, CMV cytomegalovirus, EBNA1 EBV nuclear antigen 1, VCA viral capsid antigen, IgG immunoglobulin G, VL viral load
* p < 0.0001 vs. HC
** p < 0.05 vs. HC